Drug Trial Radar · NCT03390608
Prognostic and Predictive Factors for Small Breast Tumors
Last checked: Nov 20, 2026Latest source record: Jan 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35,002
Actual
Start
Jan 1, 1977
Primary completion
Dec 31, 2014
Study completion Jul 30, 2016
Sponsor
- Lead sponsor
- Karolinska InstitutetAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Swedish Society of Medicine; The Swedish Breast Cancer Association (BRO); Swedish Breast Cancer Group
- First posted
- Jan 4, 2018
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Female only, up to 100 years
Summary
As written by the sponsor on the registry.
Because of mammography screening increasingly more women are diagnosed with centimeter or subcentimeter node-negative breast cancer (i.e., T1abN0); these tumors account for approximately 19% of all newly diagnosed breast cancers in Sweden. Although the long term relapse-free survival rates among patients with such tumors is as high as ≥90%, some reports suggest that certain patient subgroups may have rates \<75%. Firmly established prognostic and predictive factors for patients with T1abN0 tumors are, however, lacking. This is a nationwide, register-based cohort study investigating prognostic and predictive factors in women with centimeter or subcentimeter breast cancer. The study hypotheses are: 1) Established prognostic and/or predictive factors in overall breast cancer are prognostic and/or predictive factors also in centimeter or subcentimeter node-negative breast cancer; 2) The established relative reduction in risk of recurrence and death of adjuvant treatment for overall breast cancer are similar in centimeter or subcentimeter node-negative breast cancer.
Conditions
- Breast Cancer
Interventions
Endocrine therapyDrug
Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).
RadiotherapyRadiation
Radiotherapy versus no radiotherapy.
HerceptinDrug
Trastuzumab versus no trastuzumab (in women with HER2-positive disease).
ChemotherapyDrug
Chemotherapy versus no chemotherapy.
Type of breast cancer surgeryProcedure
Type of surgery (partial mastectomy, mastectomy, other).
Age at diagnosisOther
Age at diagnosis (\<35, 35-\<50, 50-\<70, ≥70).
Screen detected tumorOther
Screening detected tumor (yes, no).
Menopausal status at diagnosisOther
Menopausal status (premenopausal, postmenopausal).
Tumor sizeOther
Tumor size (≤5 mm, 6-≤10 mm).
Estrogen receptor (ER) statusOther
ER-status (positive, negative).
Tumor gradeOther
Tumor grade (1, 2, 3).
HER2-statusOther
HER2-status (positive, negative).
Intrinsic subgroups of breast cancerOther
Intrinsic subgroup proxy (Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2-positive (non-luminal), Triple negative).
Nodal statusOther
N-status (N0, N1).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Breast cancer specific deathTime frame: January 1, 1977 to December 31, 2014
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Karolinska Instiutet
Solna, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.